Clinical Trial Update: Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD) [Phase 2]

View source ↗

Summary

A Phase 2 study evaluated adding rasagiline at 1 mg or 2 mg daily to donepezil (Aricept) 10 mg in patients with mild-to-moderate Alzheimer's disease; the trial …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Dementia

Drugs mentioned

• Aricept (Donepezil)
• RASAGILINE (rasagiline)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Dementia, Alzheimer's Disease | Phase 2 | Status: COMPLETED